Immunic Reports $34.1 Million Net Loss and Advances Clinical Trials in Latest 10-Q Filing

Immunic, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $34.1 million for the quarter, an increase of 27% compared to a net loss of $26.8 million in the same period last year. For the six months ending June 30, 2026, the net loss was $66.7 million, up from $52.3 million in the prior year. The increase in losses is attributed to higher operating expenses, which rose by 30% to $35.3 million for the quarter, driven primarily by increased research and development costs and general administrative expenses.

Immunic's total operating expenses for the first half of 2026 reached $68.6 million, a 27% increase from $53.9 million in the same period of 2025. The rise in expenses was largely due to a $5.4 million increase in personnel costs, including $3.8 million related to non-cash stock compensation, and a $3.9 million increase for drug-drug interaction studies in support of a potential New Drug Application (NDA) filing. The company has not yet generated any revenue from product sales, maintaining an accumulated deficit of approximately $675.3 million as of June 30, 2026.

In terms of strategic developments, Immunic has been actively advancing its clinical programs, particularly the Phase 3 ENSURE trials for its lead candidate, vidofludimus calcium, aimed at treating relapsing multiple sclerosis (MS). The company is also preparing to initiate a Phase 3 trial for progressive MS later in 2026. Additionally, Immunic has made organizational changes, including the appointment of Erik Lundgren as CEO and Michael A. Panzara as Chief Medical Officer, both of whom are expected to play key roles in advancing the company's clinical development strategy.

Operationally, Immunic reported a cash and cash equivalents balance of approximately $155.1 million as of June 30, 2026, a significant increase from $15.5 million at the end of 2025, primarily due to a successful private placement that raised $187.3 million in February 2026. The company anticipates that its current cash reserves will be sufficient to fund operations for at least the next twelve months. Immunic's workforce has also expanded, with approximately 100 employees as of July 31, 2026, reflecting its commitment to advancing its research and development efforts.

Looking ahead, Immunic expects to continue incurring significant expenses as it progresses through its clinical trials and prepares for potential regulatory submissions. The company remains focused on maximizing the potential of its product candidates while exploring strategic alternatives for its earlier-stage programs. However, it acknowledges the inherent risks and uncertainties associated with clinical development, including the potential for delays and the need for additional funding to support its operations.